EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases (NCT07448376) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases
China20 participantsStarted 2026-03-01
Plain-language summary
The investigators conduct a single-center, prospective, observational study to explore the value of EUS-guided portal vein circulating tumor cells (PV-CTCs) and their subtypes combined with multi-omics tests in the early warning of recurrence and metastasis of resectable pancreatic cancer(RPC) and borderline resectable pancreatic cancer (BRPC).
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients with solid masses (diameter \> 1 cm) in the pancreatic area within the accessible range of endoscopic ultrasound, as indicated by clinical symptoms, laboratory tests, and imaging examinations (MRI, CT, B-ultrasound), who require biopsy to clarify the nature of the lesion.
✓. Patients diagnosed with resectable pancreatic cancer, borderline resectable pancreatic cancer, locally advanced pancreatic cancer by imaging(CT/MRI).
✓. Newly diagnosed pancreatic cancer patients who have not received radiotherapy or chemotherapy.
✓. Signed informed consent form.
✓. Patients must be able to comply with the trial requirements.
Exclusion criteria
✕. Patients with other active malignant tumors
✕. Patients with coagulation dysfunction (PLT 50,000/mm3, INR \> 1.5; roughly estimated, INR \> 1.5 is approximately equivalent to PT \> 18 seconds)
✕. Pregnant women
✕. Patients with hemorrhagic diseases
✕. Patients with a history of taking anticoagulant drugs such as aspirin and warfarin in the past week
✕. Patients with absolute contraindications to EUS examination, a history of acute pancreatitis within the past 2 weeks, a history of gastric surgery, pregnancy, severe diseases, or a history of allergy to anesthetics
What they're measuring
1
Number of circulating tumor cells in the portal vein
Timeframe: Up to 24 months
2
Subpopulation classification of portal vein circulating tumor cells
Timeframe: Up to 24 months
Trial details
NCT IDNCT07448376
SponsorHuazhong University of Science and Technology
. Patients whose EUS examination was terminated early due to esophageal stenosis, obstruction, large space-occupying lesions, rapid changes in the patient's heart rate or respiratory rate, patient intolerance, or a large amount of food residue, etc.
✕. Patients with known hepatitis C virus infection